Sage Therapeutics Inc (NASDAQ:SAGE) has a beta value of 0.95 and has seen 0.65 million shares traded in the recent trading session. The company, currently valued at $452.66M, closed the recent trade at $7.40 per share which meant it gained $0.05 on the day or 0.68% during that session. The SAGE stock price is -270.14% off its 52-week high price of $27.39 and 37.57% above the 52-week low of $4.62. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.05 million shares traded. The 3-month trading volume is 1.66 million shares.
The consensus among analysts is that Sage Therapeutics Inc (SAGE) is Hold stock at the moment, with a recommendation rating of 2.72. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 4 out of 8 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -1.36.
Sage Therapeutics Inc (NASDAQ:SAGE) trade information
Sporting 0.68% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the SAGE stock price touched $7.40 or saw a rise of 2.5%. Year-to-date, Sage Therapeutics Inc shares have moved 36.27%, while the 5-day performance has seen it change 5.56%. Over the past 30 days, the shares of Sage Therapeutics Inc (NASDAQ:SAGE) have changed 29.14%. Short interest in the company has seen 6.13 million shares shorted with days to cover at 2.54.
Wall Street analysts have a consensus price target for the stock at $13, which means that the shares’ value could jump 43.08% from the levels at last check today. The projected low price target is $5.0 while the price target rests at a high of $26.0. In that case, then, we find that the latest price level in today’s session is -251.35% off the targeted high while a plunge would see the stock lose 32.43% from the levels at last check today.
Sage Therapeutics Inc (SAGE) estimates and forecasts
Figures show that Sage Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -31.55% over the past 6 months, with this year growth rate of 28.62%, compared to 16.20% for the industry. Revenue growth from the last financial year stood is estimated to be -50.80%.
15 analysts offering their estimates for the company have set an average revenue estimate of 14.44M for the current quarter. 8 have an estimated revenue figure of 16.14M for the next ending quarter. Year-ago sales stood 77.97M and 7.9M respectively for this quarter and the next, and analysts expect sales will shrink by -81.48% for the current quarter and -50.80% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -2.28% over the past 5 years.
SAGE Dividends
Sage Therapeutics Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Sage Therapeutics Inc (NASDAQ:SAGE)’s Major holders
Insiders own 11.92% of the company shares, while shares held by institutions stand at 80.97% with a share float percentage of 91.92%. Investors are also buoyed by the number of investors in a company, with Sage Therapeutics Inc having a total of 248.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 6.42 million shares worth more than $69.68 million. As of 2024-06-30, VANGUARD GROUP INC held 10.6696% of shares outstanding.
The other major institutional holder is FMR LLC, with the holding of over 5.82 million shares as of 2024-06-30. The firm’s total holdings are worth over $63.24 million and represent 9.6836% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. As of Sep 30, 2024, the former fund manager holds about 2.80% shares in the company for having 1.71 shares of worth $12.67 million while later fund manager owns 1.63 shares of worth $12.06 million as of Nov 30, 2024, which makes it owner of about 2.66% of company’s outstanding stock.
